Thetis Pharmaceuticals Secures Additional $1.4 Million from the Helmsley Charitable Trust for Oral TP-317 IBD Program

ESSEX, CT AND NEW YORK, NY — October 17, 2026 — Thetis Pharmaceuticals, LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, oral BLT1 agonist for inflammatory bowel disease (IBD), today announced that the company has secured an additional $1.4 million in program-related investment (“PRI”) funding in the form of a loan from The Leona M. and Harry B. Helmsley Charitable Trust (“Helmsley”). The new funds supplement earlier PRI loan funding from Helmsley, including $8.975 million towards Thetis’s Phase 1b trial of TP-317 in patients with moderate-to-severe ulcerative colitis (UC) and brings Thetis’s total PRI loan funding from Helmsley to $15.4 million. Importantly, part of the loan will fund preclinical studies to validate TP-317 signaling pathways in human intestinal epithelial cells and provide data informing exploratory biomarkers of TP-317 mediated repair.

The Phase 1b is a 12-week, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety, tolerability, pharmacokinetics, and efficacy signal of TP-317, with epithelial repair and fibrosis biomarkers as exploratory readouts, relevant to disease pathways in both UC and Crohn’s disease.

Current treatment options fall short for patients with Crohn’s disease and UC, the two forms of IBD, with only a minority of patients achieving lasting remission. Effective therapy requires not only reducing inflammation but also actively repairing the intestinal lining to shield underlying tissues from pro-inflammatory triggers and preventing formation of fibrosis leading to strictures and other complications. TP-317 has shown anti-inflammatory, epithelial repair and anti-fibrogenic effects in preclinical colitis models. Supported by a previous PRI from Helmsley, Thetis completed a Phase 1a study in healthy volunteers that demonstrated target engagement with oral TP-317.

“Helmsley is committed to supporting therapeutic development to address the underlying drivers of disease progression in Crohn’s disease,” said Jessica Langer, Ph.D., Program Officer at Helmsley. “That’s why we support Thetis with TP-317, a novel, promising drug candidate with the potential to alter IBD disease course and lead to intestinal healing.”

“Helmsley’s continued support allows us to evaluate TP-317 in patients with ulcerative colitis, with endpoints that capture epithelial repair and fibrosis in addition to clinical response,” said Gary Mathias, co-founder and CEO of Thetis. “TP-317 provides a non-immunosuppressive mechanism of action designed to complement the mucosal healing achieved with advanced therapies.”

About Thetis Pharmaceuticals

Thetis Pharmaceuticals is a clinical-stage pharmaceutical company developing new therapies for IBD. Its lead candidate, TP-317, is a first-in-class, oral drug based on Resolvin E1 (RvE1), an endogenous lipid mediator that engages the BLT1 receptor to activate the body’s capacity to restore tissue and immune homeostasis. TP-317 is being developed as a combination partner designed to add epithelial repair and fibrosis reduction to established IBD therapies without additional immunosuppression. Thetis is supported by the Leona M. and Harry B. Helmsley Charitable Trust, the Crohn’s & Colitis Foundation, the Kenneth Rainin Foundation, the National Institutes of Health (NIH), and private investors.

Contact Information

Tracy Lessor
TLOW Communications
617-519-9827
tracy@tlowcommunications.com

Next
Next

Thetis Pharmaceuticals Receives Regulatory Approval in Moldova for Phase 1b Trial of Oral TP-317 in Ulcerative Colitis